Albireo Pharma (FRA:BDQM) Accounts Payable : €7.02 Mil (As of Sep. 2022)

View and export this data going back to 2007. Start your Free Trial

What is Albireo Pharma Accounts Payable?

Albireo Pharma's Accounts Payable for the quarter that ended in Sep. 2022 was €7.02 Mil.

Albireo Pharma's quarterly Accounts Payable declined from Mar. 2022 (€5.78 Mil) to Jun. 2022 (€5.10 Mil) but then increased from Jun. 2022 (€5.10 Mil) to Sep. 2022 (€7.02 Mil).

Albireo Pharma's annual Accounts Payable increased from Dec. 2019 (€4.31 Mil) to Dec. 2020 (€4.34 Mil) and increased from Dec. 2020 (€4.34 Mil) to Dec. 2021 (€5.77 Mil).

Albireo Pharma Accounts Payable Historical Data

The historical data trend for Albireo Pharma's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Albireo Pharma Accounts Payable Chart

Albireo Pharma Annual Data

Trend

Sep12

Sep13

Sep14

Sep15

Sep16

Dec17

Dec18

Dec19

Dec20

Dec21

Accounts Payable

Get a 7-Day Free Trial

1.14

3.83

4.31

4.34

5.77

Albireo Pharma Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Accounts Payable	Get a 7-Day Free Trial															6.14	5.77	5.78	5.10	7.02

Albireo Pharma Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Albireo Pharma Accounts Payable Related Terms

Thank you for viewing the detailed overview of Albireo Pharma's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Albireo Pharma (FRA:BDQM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Albireo Pharma Inc (FRA:BDQM) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

53 State Street, 19th Floor, Boston, MA, USA, 02109

Website

https://www.albireopharma.com

Albireo Pharma Inc is a commercial-stage biopharmaceutical company. It focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. The Company's product pipeline includes Bylvay, which is approved in the United States and Europe; elobixibat, which is approved in Japan for the treatment of chronic constipation; A3907, its Phase 1 lead candidate for the treatment of adult liver diseases; and A2342, it's a lead preclinical candidate for the treatment of adult viral and liver diseases.

Albireo Pharma (FRA:BDQM) Headlines

No Headlines